AI assistant
PIRAMAL PHARMA LIMITED — Call Transcript 2025
Oct 24, 2025
59525_rns_2025-10-24_9d5d9aef-7a3d-4708-907a-d37de3408eed.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [145 x 60] intentionally omitted <==
24[th] October, 2025
BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635
National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA
Sub: Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)
Dear Sir / Madam,
Pursuant to Regulation 30(6) of the SEBI Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts.
Kindly take this on record.
Thanking you,
Yours truly,
For Piramal Pharma Limited
Digitally signed TANYA by TANYA SANISH SANISH Date: 2025.10.24 11:32:46 +05'30'
Tanya Sanish Company Secretary
Encl: a/a
Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India T: +91 22 3802 3000 / 4000; Email : [email protected] piramalpharma.com
==> picture [145 x 60] intentionally omitted <==
Q2 and H1 FY2026 Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 06[th] November 2025 from 9:30 AM to 10:15 AM (IST) to discuss its Q2 and H1 FY2026 Results.
The dial-in details for the call are as under:
| Event | Location & Time | Telephone Number |
|---|---|---|
| Conference call on 06thNovember, 2025 |
India – 09:30 AM IST | +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) |
| 1 800 120 1221(Toll free number) | ||
| USA – 11:00 PM (Eastern Time – New York) |
Toll free number 18667462133 |
|
| UK – 04:00 AM (London Time) |
Toll free number 08081011573 |
|
| Singapore – 12:00 PM (Singapore Time) |
Toll free number 8001012045 |
|
| Hong Kong – 12:00 PM (HongKongTime) |
Toll free number 800964448 |
|
| Express Join with Diamond Pass™ |
Please use this link for prior registration to reduce wait time at the time of joining the call –Click Here |
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE:PPLPHARMA I BSE:543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics and vaccine segments.
For more information, visit: Piramal Pharma | LinkedIn
- Includes one facility via PPL’s minority investment in Yapan Bio
For Queries: Gagan Borana Investor Relations & Enterprise Risk Management [email protected]
Piramal Pharma Limited
CIN: L24297MH2020PLC338592 Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India T: +91 22 3802 3000 / 4000; Email : [email protected]
piramalpharma.com